EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Real‐world evidence for amyloid‐targeted therapies: Lecanemab and donanemab

Ryan Hakim iD, Kristofer Harris, Livia Merrill, Amanda Falk-Vargas, Eileen Whalen, Tianxu Xia, Olga Ochoa, David Hunter, Paul Ernest Schulz

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-07 · 18 (3)

DOI: 10.1002/dad2.70404 ↗

At a glance

Journal article in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, published online on 2026-08-26. Written by Ryan Hakim and 8 co-authors. Institution: Department of Neurology The McGovern Medical School of UTHealth Houston Texas USA. Cited 2 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

INTRODUCTION Real‐world safety data on amyloid‐targeted therapies in early Alzheimer's disease remain limited, particularly for modified donanemab titration and direct lecanemab–donanemab comparisons. METHODS Retrospective review of 172 amyloid‐positive patients treated with lecanemab ( n = 89) or donanemab (original titration n = 21; modified n = 62). The cohort included patients with ≥2 chronic comorbidities (72.7%), systemic autoimmune or hematologic disorders, and concurrent immunomodulators. RESULTS Amyloid‐related imaging abnormalities (ARIA) occurred in 11.2% (10/89) with lecanemab and 13.3% (11/83) with donanemab—less than in pivotal trials. Modified donanemab titration reduced ARIA versus the original protocol (8.1% vs 28.6%; p = 0.03) and TRAILBLAZER‐ALZ 6 (23.6%). No anaphylaxis occurred. Surveillance magnetic resonance imaging captured 95.2% of ARIA events. Within‐center comparison showed comparable safety between lecanemab and modified‐titration donanemab (all p ’s > 0.40). IRRs occurred in 12.0% (donanemab) and 9.0% (lecanemab). DISCUSSION In a real‐world cohort representing patients excluded from trials, ARIA and IRR rates matched or improved upon pivotal trials, supporting safe ATT use under FDA‐approved MRI intervals.

Subjects

Author keywords

APOE ε4ARIA‐EARIA‐HAlzheimer's diseaseInfusion‐related reactionsMRI surveillanceamyloid‐related imaging abnormalitiesanti‐amyloid monoclonal antibodiesdonanemablecanemabmodified titration dosingreal‐world evidencesafety and tolerability

Authors and institutions

  • Department of Neurology The McGovern Medical School of UTHealth Houston Texas USA.
  • UTHealth Graduate School of Biomedical Sciences Houston Texas USA.

ORCID profiles: Ryan Hakim

Cite

APA

Hakim, R., Harris, K., Merrill, L., Falk-Vargas, A., Whalen, E., Xia, T., Ochoa, O., Hunter, D., & Schulz, P. E. (2026). Real‐world evidence for amyloid‐targeted therapies: Lecanemab and donanemab. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 18(3). https://doi.org/10.1002/dad2.70404

Vancouver

Hakim R, Harris K, Merrill L, Falk-Vargas A, Whalen E, Xia T, et al. Real‐world evidence for amyloid‐targeted therapies: Lecanemab and donanemab. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2026;18(3). doi:10.1002/dad2.70404

BibTeX
@article{Hakim2026,
  author = {Hakim, Ryan and Harris, Kristofer and Merrill, Livia and Falk-Vargas, Amanda and Whalen, Eileen and Xia, Tianxu and Ochoa, Olga and Hunter, David and Schulz, Paul Ernest},
  title = {Real‐world evidence for amyloid‐targeted therapies: Lecanemab and donanemab},
  journal = {Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring},
  year = {2026},
  volume = {18},
  number = {3},
  doi = {10.1002/dad2.70404}
}
Start for free →